TD Asset Management
IOVA icon

TD Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

TD Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Sell
245,052
-95,200
-28% -$362K ﹤0.01% 1093
2026
Q1 		$1.19M Buy
340,252
+286,800
+537% +$917K ﹤0.01% 1070
2025
Q4 		$146K Sell
53,452
-86,426
-62% -$200K ﹤0.01% 1228
2025
Q3 		$304K Hold
139,878
– – ﹤0.01% 1204
2025
Q2 		$241K Hold
139,878
– – ﹤0.01% 1173
2025
Q1 		$466K Sell
139,878
-171,200
-55% -$883K ﹤0.01% 1149
2024
Q4 		$2.3M Sell
311,078
-58,200
-16% -$539K ﹤0.01% 970
2024
Q3 		$3.55M Buy
369,278
+84,400
+30% +$800K ﹤0.01% 871
2024
Q2 		$2.28M Sell
284,878
-220,400
-44% -$2.36M ﹤0.01% 951
2024
Q1 		$7.49M Buy
505,278
+247,818
+96% +$2.88M 0.01% 678
2023
Q4 		$2.09M Sell
257,460
-78,618
-23% -$411K ﹤0.01% 991
2023
Q3 		$1.53M Buy
336,078
+168,522
+101% +$1.1M ﹤0.01% 1035
2023
Q2 		$1.18M Buy
167,556
+50,900
+44% +$364K ﹤0.01% 1091
2023
Q1 		$713K Buy
116,656
+2,000
+2% +$13.8K ﹤0.01% 1202
2022
Q4 		$733K Sell
114,656
-32,900
-22% -$257K ﹤0.01% 1202
2022
Q3 		$1.41M Buy
147,556
+12,300
+9% +$142K ﹤0.01% 1097
2022
Q2 		$1.49M Sell
135,256
-25,712
-16% -$337K ﹤0.01% 1090
2022
Q1 		$2.68M Buy
160,968
+22,244
+16% +$344K ﹤0.01% 996
2021
Q4 		$2.65M Buy
138,724
+7,280
+6% +$160K ﹤0.01% 1067
2021
Q3 		$3.24M Hold
131,444
– – ﹤0.01% 946
2021
Q2 		$2.93M Sell
131,444
-27,820
-17% -$723K ﹤0.01% 975
2021
Q1 		$5.04M Sell
159,264
-36,878
-19% -$1.53M 0.01% 816
2020
Q4 		$9.1M Buy
196,142
+23,827
+14% +$946K 0.01% 617
2020
Q3 		$5.67M Hold
172,315
– – 0.01% 669
2020
Q2 		$4.73M Buy
172,315
+15,507
+10% +$510K 0.01% 674
2020
Q1 		$4.69M Sell
156,808
-10,800
-6% -$286K 0.01% 634
2019
Q4 		$4.64M Sell
167,608
-4,200
-2% -$95.5K 0.01% 730
2019
Q3 		$3.13M Buy
171,808
+6,500
+4% +$144K ﹤0.01% 805
2019
Q2 		$4.05M Buy
165,308
+55,800
+51% +$840K 0.01% 728
2019
Q1 		$1.04M Sell
109,508
-500
-0.5% -$4.86K ﹤0.01% 1032
2018
Q4 		$974K Buy
110,008
+7,608
+7% +$73.4K ﹤0.01% 1063
2018
Q3 		$1.15M Buy
102,400
+3,600
+4% +$51.1K ﹤0.01% 1127
2018
Q2 		$1.26M Buy
98,800
+22,400
+29% +$327K ﹤0.01% 1073
2018
Q1 		$1.29M Buy
+76,400
New +$1.16M ﹤0.01% 993
2016
Q4 		– Sell
-14,931
Closed -$123K – 1388
2016
Q3 		$123K Buy
+14,931
New +$126K ﹤0.01% 1384

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TD Asset Management's IOVA Position: Q2 2026 in Review

TD Asset Management reduced its Iovance Biotherapeutics (IOVA) stake by 28% in Q2 2026, selling an estimated $362K and leaving 245,052 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1093.

TD Asset Management first reported a position in IOVA in Q3 2016 and has held it in 35 quarters since. The position peaked at $9.1M in Q4 2020. 209 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • TD Asset Management held 245,052 shares of Iovance Biotherapeutics worth $1.02M as of Q2 2026.
  • TD Asset Management sold 95,200 Iovance Biotherapeutics shares in Q2 2026, an estimated $362K.
  • Iovance Biotherapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #1093 holding.
  • TD Asset Management first reported a position in Iovance Biotherapeutics in Q3 2016 and has held it in 35 quarters since.
  • TD Asset Management's Iovance Biotherapeutics position peaked at $9.1M in Q4 2020.
  • 209 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.